PressNovember 3, 2021 COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
PressNovember 2, 2021 Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia
PressOctober 29, 2021 MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol through iSTRYM, MINDCURE’s Digital Therapeutics Platform
PressOctober 29, 2021 Psychedelics Venture Capital Firm Iter Investments to Exhibit/Host Events at Wonderland: Miami by Microdose from Nov. 8-9, 2021
PressOctober 29, 2021 Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program
PressOctober 29, 2021 Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study using Kernel Flow Technology
PressOctober 22, 2021 Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder
PressOctober 20, 2021 Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
PressOctober 19, 2021 Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System
PressOctober 18, 2021 Clearmind Medicine Partners With Clinipace to Commence Processes Towards FDA Approval
PressOctober 15, 2021 Levitee Labs Signs Letter of Intent to Acquire Calgary Addiction and Compounding Pharmacy
PressOctober 12, 2021 Cybin Files an International Patent Application Covering Psychedelic Delivery Methods
PressOctober 11, 2021 Atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression
